Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018

Authors

Shannon N Westin, University of Texas MD Anderson Cancer Center
Melinda Louie-Gao, GlaxoSmithKline
Divya Gupta, GlaxoSmithKline
Premal H Thaker, Washington University School of Medicine in St. Louis

Journal

Future Oncology

Publication Date

11-1-2021

Volume

17

Issue

32

First Page

4263

Last Page

4274

Document Type

Open Access Publication

DOI

10.2217/fon-2021-0018

Rights and Permissions

Westin SN, Louie-Gao M, Gupta D, Thaker PH. Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018. Future Oncol. 2021 Nov;17(32):4263-4274. doi: 10.2217/fon-2021-0018. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. For full bibliographic citation, please refer to the version available at www.futuremedicine.com.

Recommended Citation

Westin, Shannon N; Louie-Gao, Melinda; Gupta, Divya; and Thaker, Premal H, "Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018." Future Oncology. 17, 32. 4263 - 4274. (2021).
https://digitalcommons.wustl.edu/oa_4/408